| # | Title | Journal | Year | Citations |
|---|
| 1 | Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) | Autophagy | 2016 | 4,701 |
| 2 | MYC on the Path to Cancer | Cell | 2012 | 2,577 |
| 3 | Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 | Autophagy | 2021 | 1,430 |
| 4 | TRAIL and apoptosis induction by TNF-family death receptors | Oncogene | 2003 | 796 |
| 5 | Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects | Cancer Cell | 2004 | 710 |
| 6 | Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 | Annals of Oncology | 2019 | 641 |
| 7 | Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study | Lancet Oncology, The | 2020 | 544 |
| 8 | Clinical Activity and Immune Modulation in Cancer Patients Treated With CP-870,893, a Novel CD40 Agonist Monoclonal Antibody | Journal of Clinical Oncology | 2007 | 458 |
| 9 | Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma | Immunity | 2016 | 458 |
| 10 | Racial Differences in Trust in Health Care Providers | Archives of Internal Medicine | 2006 | 340 |
| 11 | Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up | Annals of Oncology | 2019 | 329 |
| 12 | Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer | Science Translational Medicine | 2018 | 326 |
| 13 | Cancer and Inflammation: Promise for Biologic Therapy | Journal of Immunotherapy | 2010 | 293 |
| 14 | EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes | Journal of Clinical Oncology | 2019 | 286 |
| 15 | Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families | Journal of Clinical Oncology | 2020 | 270 |
| 16 | Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy | Gynecologic Oncology | 2016 | 252 |
| 17 | Adoptive Immunotherapy for Cancer or Viruses | Annual Review of Immunology | 2014 | 240 |
| 18 | Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease | New England Journal of Medicine | 2012 | 235 |
| 19 | Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study | Lancet Oncology, The | 2015 | 205 |
| 20 | Menin: a scaffold protein that controls gene expression and cell signaling | Trends in Biochemical Sciences | 2013 | 200 |
| 21 | Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21 | Nature Genetics | 2011 | 198 |
| 22 | Identification of High-Risk Patients Among Those Diagnosed With Thin Cutaneous Melanomas | Journal of Clinical Oncology | 2007 | 188 |
| 23 | HIF2α inhibition promotes p53 pathway activity, tumor cell death, and radiation responses | Proceedings of the National Academy of Sciences of the United States of America | 2009 | 176 |
| 24 | Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. | Journal of Clinical Oncology | 2017 | 160 |
| 25 | A phase 2 trial of R1507, a monoclonal antibody to the insulin‐like growth factor‐1 receptor (IGF‐1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study | Cancer | 2014 | 158 |
| 26 | Interplay between Notch1 and Notch3 promotes EMT and tumor initiation in squamous cell carcinoma | Nature Communications | 2017 | 155 |
| 27 | APOBEC3 Proteins in Viral Immunity | Journal of Immunology | 2015 | 147 |
| 28 | Follow-up care of cancer survivors: challenges and solutions | Lancet Oncology, The | 2017 | 146 |
| 29 | Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety | Annals of Oncology | 2016 | 136 |
| 30 | T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma | Blood Advances | 2019 | 133 |
| 31 | Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey | BMC Cancer | 2016 | 132 |
| 32 | Prevalence of breast cancer treatment sequelae over 6 years of follow‐up | Cancer | 2012 | 126 |
| 33 | Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study | Lancet Oncology, The | 2019 | 124 |
| 34 | Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC) | Cancer Treatment Reviews | 2014 | 122 |
| 35 | Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer | Nature Communications | 2018 | 122 |
| 36 | Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study. | Journal of Clinical Oncology | 2018 | 107 |
| 37 | A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802 | Medical Oncology | 2012 | 105 |
| 38 | Palbociclib (PD0332991)—a Selective and Potent Cyclin-Dependent Kinase Inhibitor | JAMA Oncology | 2016 | 103 |
| 39 | Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials | Clinical Cancer Research | 2017 | 99 |
| 40 | The rise and fall of prostate brachytherapy: Use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base | Cancer | 2014 | 96 |
| 41 | Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood–brain barrier divide | Expert Opinion on Drug Delivery | 2013 | 92 |
| 42 | Mutant KRAS in the initiation of pancreatic cancer | Biochimica Et Biophysica Acta: Reviews on Cancer | 2005 | 89 |
| 43 | Predictors of Regional Nodal Disease in Patients With Thin Melanomas | Annals of Surgical Oncology | 2006 | 89 |
| 44 | MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels | Cancer Research | 2018 | 87 |
| 45 | Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT) | Bone Marrow Transplantation | 2019 | 86 |
| 46 | Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy | Biology of Blood and Marrow Transplantation | 2019 | 85 |
| 47 | Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer | BMC Cancer | 2011 | 84 |
| 48 | Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck | JAMA Oncology | 2018 | 84 |
| 49 | Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study | BJU International | 2011 | 83 |
| 50 | Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants | Genetics in Medicine | 2020 | 82 |
